SG11202102432TA - Immunomodulators, compositions and methods there of - Google Patents
Immunomodulators, compositions and methods there ofInfo
- Publication number
- SG11202102432TA SG11202102432TA SG11202102432TA SG11202102432TA SG11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA SG 11202102432T A SG11202102432T A SG 11202102432TA
- Authority
- SG
- Singapore
- Prior art keywords
- immunomodulators
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018105582 | 2018-09-13 | ||
PCT/CN2019/105685 WO2020052650A1 (en) | 2018-09-13 | 2019-09-12 | Immunomodulators, compositions and methods there of |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102432TA true SG11202102432TA (en) | 2021-04-29 |
Family
ID=69776767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102432TA SG11202102432TA (en) | 2018-09-13 | 2019-09-12 | Immunomodulators, compositions and methods there of |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220041583A1 (ko) |
EP (1) | EP3849972A4 (ko) |
JP (1) | JP7453963B2 (ko) |
KR (1) | KR20210061359A (ko) |
CN (1) | CN112654617A (ko) |
AU (1) | AU2019339703B2 (ko) |
CA (1) | CA3112286A1 (ko) |
EA (1) | EA202190766A1 (ko) |
IL (1) | IL281164A (ko) |
SG (1) | SG11202102432TA (ko) |
WO (1) | WO2020052650A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210300909A1 (en) * | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
WO2021233454A1 (zh) * | 2020-05-22 | 2021-11-25 | 上海长森药业有限公司 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3377488T2 (ro) * | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
AU2017305399A1 (en) * | 2016-08-03 | 2019-01-31 | Arising International, Inc. | Symmetric or semi-symmetric compounds useful as immunomodulators |
US10882844B2 (en) * | 2016-12-20 | 2021-01-05 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
ES2899402T3 (es) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
MX2020010321A (es) * | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
US20210300909A1 (en) * | 2018-07-19 | 2021-09-30 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
CA3128426A1 (en) * | 2019-01-31 | 2020-08-06 | Betta Pharmaceuticals Co., Ltd. | Immunomodulators, compositions and methods thereof |
-
2019
- 2019-09-12 SG SG11202102432TA patent/SG11202102432TA/en unknown
- 2019-09-12 CA CA3112286A patent/CA3112286A1/en active Pending
- 2019-09-12 AU AU2019339703A patent/AU2019339703B2/en active Active
- 2019-09-12 US US17/275,450 patent/US20220041583A1/en active Pending
- 2019-09-12 JP JP2021513224A patent/JP7453963B2/ja active Active
- 2019-09-12 EA EA202190766A patent/EA202190766A1/ru unknown
- 2019-09-12 WO PCT/CN2019/105685 patent/WO2020052650A1/en unknown
- 2019-09-12 EP EP19860432.4A patent/EP3849972A4/en active Pending
- 2019-09-12 CN CN201980057938.8A patent/CN112654617A/zh active Pending
- 2019-09-12 KR KR1020217010081A patent/KR20210061359A/ko unknown
-
2021
- 2021-03-01 IL IL281164A patent/IL281164A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7453963B2 (ja) | 2024-03-21 |
US20220041583A1 (en) | 2022-02-10 |
AU2019339703A1 (en) | 2021-04-08 |
CN112654617A (zh) | 2021-04-13 |
EP3849972A4 (en) | 2022-06-01 |
EP3849972A1 (en) | 2021-07-21 |
WO2020052650A1 (en) | 2020-03-19 |
CA3112286A1 (en) | 2020-03-19 |
KR20210061359A (ko) | 2021-05-27 |
JP2022511303A (ja) | 2022-01-31 |
IL281164A (en) | 2021-04-29 |
AU2019339703B2 (en) | 2024-06-06 |
EA202190766A1 (ru) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285215A (en) | Training modulators, preparations and their methods | |
EP3774750A4 (en) | Immunomodulators, compositions and methods thereof | |
ZA202007839B (en) | Polymerases, compositions, and methods of use | |
ZA202007838B (en) | Polymerases, compositions, and methods of use | |
IL265045B1 (en) | Variants of endonuclease pd-1, compositions and methods of use | |
IL280134A (en) | Anti-CD112R preparations and methods | |
IL268970A (en) | New preparations and methods | |
IL313037A (en) | CBLB endonuclease variants, compositions and methods of use | |
GB201807325D0 (en) | Compositions and methods | |
GB202201859D0 (en) | Novel methods and compositions | |
EP3526334A4 (en) | TGFBETA R2 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE | |
EP3504335A4 (en) | TIM3 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE | |
IL276135A (en) | Preparations and methods of use | |
SG11202104448WA (en) | Compositions and methods | |
GB2576614B (en) | Compositions, uses and methods | |
IL277786A (en) | AAV preparations, methods of preparation and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
GB201804163D0 (en) | Uses, compositions and methods | |
IL281164A (en) | Immunomodulators, preparations and methods thereof | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
GB201819987D0 (en) | Methods and compositions | |
GB201817444D0 (en) | Methods and compositions | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
EP3313399A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING RIT1 |